Compare Aventis Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs UNICHEM LAB - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA UNICHEM LAB SANOFI INDIA/
UNICHEM LAB
 
P/E (TTM) x 34.8 61.9 56.2% View Chart
P/BV x 6.1 0.7 916.3% View Chart
Dividend Yield % 1.4 2.1 68.7%  

Financials

 SANOFI INDIA   UNICHEM LAB
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
UNICHEM LAB
Mar-19
SANOFI INDIA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs6,840292 2,342.5%   
Low Rs4,630182 2,544.0%   
Sales per share (Unadj.) Rs1,203.1167.7 717.6%  
Earnings per share (Unadj.) Rs165.3-3.6 -4,551.8%  
Cash flow per share (Unadj.) Rs209.95.9 3,532.0%  
Dividends per share (Unadj.) Rs84.004.00 2,100.0%  
Dividend yield (eoy) %1.51.7 86.8%  
Book value per share (Unadj.) Rs963.6372.3 258.9%  
Shares outstanding (eoy) m23.0370.38 32.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.81.4 337.2%   
Avg P/E ratio x34.7-65.3 -53.2%  
P/CF ratio (eoy) x27.339.9 68.5%  
Price / Book Value ratio x6.00.6 934.8%  
Dividend payout %50.8-110.2 -46.1%   
Avg Mkt Cap Rs m132,07816,680 791.8%   
No. of employees `0003.32.6 126.9%   
Total wages/salary Rs m4,0682,393 170.0%   
Avg. sales/employee Rs Th8,393.84,535.2 185.1%   
Avg. wages/employee Rs Th1,232.4919.8 134.0%   
Avg. net profit/employee Rs Th1,153.0-98.2 -1,174.1%   
INCOME DATA
Net Sales Rs m27,70811,801 234.8%  
Other income Rs m897984 91.1%   
Total revenues Rs m28,60512,785 223.7%   
Gross profit Rs m6,235-835 -746.8%  
Depreciation Rs m1,027674 152.4%   
Interest Rs m775 9.3%   
Profit before tax Rs m6,098-600 -1,016.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,292-343 -667.3%   
Profit after tax Rs m3,806-256 -1,489.5%  
Gross profit margin %22.5-7.1 -318.1%  
Effective tax rate %37.657.3 65.6%   
Net profit margin %13.7-2.2 -634.3%  
BALANCE SHEET DATA
Current assets Rs m15,92220,384 78.1%   
Current liabilities Rs m6,2355,029 124.0%   
Net working cap to sales %35.0130.1 26.9%  
Current ratio x2.64.1 63.0%  
Inventory Days Days64105 60.8%  
Debtors Days Days21135 15.5%  
Net fixed assets Rs m7,5399,023 83.5%   
Share capital Rs m230141 163.4%   
"Free" reserves Rs m21,96226,058 84.3%   
Net worth Rs m22,19226,199 84.7%   
Long term debt Rs m00-   
Total assets Rs m29,83931,496 94.7%  
Interest coverage x872.1-7.0 -12,504.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.4 247.8%   
Return on assets %12.8-0.6 -2,231.9%  
Return on equity %17.2-1.0 -1,758.4%  
Return on capital %27.5-2.0 -1,376.0%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,5878,188 92.7%   
Fx outflow Rs m7,145596 1,198.8%   
Net fx Rs m4427,592 5.8%   
CASH FLOW
From Operations Rs m3,739-3,278 -114.1%  
From Investments Rs m-731-2,860 25.6%  
From Financial Activity Rs m-1,972-24 8,148.8%  
Net Cashflow Rs m1,036-4,690 -22.1%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 15.1 95.4%  
FIIs % 14.6 3.0 486.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 31.7 33.1%  
Shareholders   15,184 20,176 75.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  GSK PHARMA  DR. DATSONS LABS  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 16, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ASTRAZENECA PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS